Arcus Biosciences financials
$25.65+2.56%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41.0M | $17.0M | $33.0M | $26.0M | $160.0M | $28.0M | $26.0M | $48.0M | $39.0M | $145.0M | $31.0M | $32.0M |
| Gross profit | $41.0M | $17.0M | $33.0M | $26.0M | $160.0M | $28.0M | $26.0M | $48.0M | $39.0M | $145.0M | $31.0M | $32.0M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$96.0M | -$134.0M | -$114.0M | -$142.0M | -$8.0M | -$122.0M | -$103.0M | -$105.0M | -$106.0M | -$16.0M | -$91.0M | -$80.0M |
| Net income | -$91.0M | -$128.0M | -$106.0M | -$135.0M | $0.00 | -$112.0M | -$94.0M | -$92.0M | -$93.0M | -$4.0M | -$81.0M | -$71.0M |
| Net margin | −222.0% | −752.9% | −321.2% | −519.2% | 0.0% | −400.0% | −361.5% | −191.7% | −238.5% | −2.8% | −261.3% | −221.9% |
| Diluted EPS | $-0.72 | $-1.02 | $-0.90 | $-1.27 | $0.00 | $-1.14 | $-1.03 | $-1.00 | $-1.02 | $-0.05 | $-1.08 | $-0.94 |
| EBITDA | -$93.0M | -$132.0M | -$111.0M | -$140.0M | -$6.0M | -$119.0M | -$100.0M | -$103.0M | -$106.0M | $7.0M | -$91.0M | -$79.0M |
| Operating cash flow | -$119.0M | -$138.0M | -$120.0M | -$97.0M | -$133.0M | -$132.0M | -$100.0M | $26.0M | $0.00 | -$2.0M | -$88.0M | -$63.0M |
| Free cash flow | -$119.0M | -$138.0M | -$121.0M | -$97.0M | -$133.0M | -$133.0M | -$101.0M | $25.0M | $0.00 | -$6.0M | -$94.0M | -$73.0M |
| Diluted shares | 126.1M | 125.4M | 118.2M | 106.5M | 106.5M | 98.4M | 91.7M | 91.4M | 91.1M | 86.2M | 75.2M | 74.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $150.0M | $201.0M | $222.0M | $238.0M | $248.0M | $192.0M |
| Short-term investments | $552.0M | $621.0M | $759.0M | $593.0M | $663.0M | $805.0M |
| Total debt | $101.0M | $100.0M | $99.0M | $98.0M | $97.0M | $48.0M |
| Total assets | $924.0M | $997.0M | $1.14B | $974.0M | $1.07B | $1.16B |
| Total liabilities | $460.0M | $473.0M | $508.0M | $538.0M | $526.0M | $625.0M |
| Shareholders' equity | $464.0M | $524.0M | $631.0M | $436.0M | $549.0M | $531.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology